Abdominal pain in patients with inflammatory bowel disease in remission: A prospective study on contributing factors

IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
L. M. Janssen, A. Rezazadeh Ardabili, M. J. L. Romberg-Camps, B. Winkens, R. J. van den Broek, J. Hulst, H. J. A. Verwijs, D. Keszthelyi, D. M. A. E. Jonkers, A. A. van Bodegraven, M. J. Pierik, Z. Mujagic
{"title":"Abdominal pain in patients with inflammatory bowel disease in remission: A prospective study on contributing factors","authors":"L. M. Janssen,&nbsp;A. Rezazadeh Ardabili,&nbsp;M. J. L. Romberg-Camps,&nbsp;B. Winkens,&nbsp;R. J. van den Broek,&nbsp;J. Hulst,&nbsp;H. J. A. Verwijs,&nbsp;D. Keszthelyi,&nbsp;D. M. A. E. Jonkers,&nbsp;A. A. van Bodegraven,&nbsp;M. J. Pierik,&nbsp;Z. Mujagic","doi":"10.1111/apt.17718","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Abdominal pain is highly prevalent in patients with inflammatory bowel disease (IBD) in remission, but the aetiology is incompletely understood.</p>\n </section>\n \n <section>\n \n <h3> Aim</h3>\n \n <p>To investigate the association of clinical, lifestyle and psychosocial factors with abdominal pain in patients with IBD in remission.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We performed a prospective multicentre study enrolling consecutive patients with IBD. Data were collected between 1 January 2020 and 1 July 2021, using myIBDcoach, an established remote monitoring platform for IBD. Chronic abdominal pain in IBD in remission (IBD<i>remission</i>Pain+) was defined as abdominal pain score ≥3 (0–10 NRS) on ≥1/3 of all assessments, combined with faecal calprotectin &lt;150 μg/g in 90 days around periodic assessments. Disease activity, lifestyle and psychosocial factors were assessed every 1–3 months during 18 months. Using linear mixed models, the association of these factors with abdominal pain over time was analysed.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We included 559 patients, of whom 429 (76.7%) remained in biochemical remission. Of these, 198 (46.2%) fulfilled the criteria for chronic abdominal pain. IBD<i>remission</i>Pain+ patients were characterised by female sex, younger age, higher BMI, and shorter disease duration. They reported more often or higher levels of stress, fatigue, depressive and anxiety symptoms, and life events (all <i>p</i> &lt; 0.001). In the multivariable analysis, sex, disease entity, fatigue, depressive symptoms and life events were associated with abdominal pain over time (all <i>p</i> &lt; 0.05).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>In this cohort of patients with IBD in remission, abdominal pain was common and associated with psychosocial factors. A more holistic treatment approach for patients with IBD suffering from abdominal pain may improve quality of care and subjective wellbeing.</p>\n </section>\n </div>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"58 10","pages":"1041-1051"},"PeriodicalIF":6.6000,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.17718","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apt.17718","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 3

Abstract

Background

Abdominal pain is highly prevalent in patients with inflammatory bowel disease (IBD) in remission, but the aetiology is incompletely understood.

Aim

To investigate the association of clinical, lifestyle and psychosocial factors with abdominal pain in patients with IBD in remission.

Methods

We performed a prospective multicentre study enrolling consecutive patients with IBD. Data were collected between 1 January 2020 and 1 July 2021, using myIBDcoach, an established remote monitoring platform for IBD. Chronic abdominal pain in IBD in remission (IBDremissionPain+) was defined as abdominal pain score ≥3 (0–10 NRS) on ≥1/3 of all assessments, combined with faecal calprotectin <150 μg/g in 90 days around periodic assessments. Disease activity, lifestyle and psychosocial factors were assessed every 1–3 months during 18 months. Using linear mixed models, the association of these factors with abdominal pain over time was analysed.

Results

We included 559 patients, of whom 429 (76.7%) remained in biochemical remission. Of these, 198 (46.2%) fulfilled the criteria for chronic abdominal pain. IBDremissionPain+ patients were characterised by female sex, younger age, higher BMI, and shorter disease duration. They reported more often or higher levels of stress, fatigue, depressive and anxiety symptoms, and life events (all p < 0.001). In the multivariable analysis, sex, disease entity, fatigue, depressive symptoms and life events were associated with abdominal pain over time (all p < 0.05).

Conclusion

In this cohort of patients with IBD in remission, abdominal pain was common and associated with psychosocial factors. A more holistic treatment approach for patients with IBD suffering from abdominal pain may improve quality of care and subjective wellbeing.

Abstract Image

炎症性肠病缓解期患者的腹痛:一项影响因素的前瞻性研究。
背景:腹痛在炎症性肠病(IBD)缓解期患者中非常普遍,但其病因尚不完全清楚。目的:探讨临床、生活方式和心理社会因素与IBD缓解期患者腹痛的关系。方法:我们进行了一项前瞻性多中心研究,纳入了连续的IBD患者。数据是在2020年1月1日至2021年7月1日期间使用myIBDcoach收集的,myIBDoach是一个已建立的IBD远程监测平台。IBD缓解期的慢性腹痛(IBDremissionPain+)定义为所有评估中≥1/3的腹痛评分≥3(0-10 NRS),并结合粪便钙卫蛋白。结果:我们纳入559名患者,其中429名(76.7%)仍处于生化缓解状态。其中198例(46.2%)符合慢性腹痛的标准。IBDremissionPain+患者的特点是女性、年龄较小、BMI较高、病程较短。他们报告了更频繁或更高水平的压力、疲劳、抑郁和焦虑症状以及生活事件(均p 结论:在这组IBD缓解期患者中,腹痛很常见,并与心理社会因素有关。对患有腹痛的IBD患者采用更全面的治疗方法可能会提高护理质量和主观幸福感。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.60
自引率
7.90%
发文量
527
审稿时长
3-6 weeks
期刊介绍: Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信